.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,191,139

« Back to Dashboard

Details for Patent: 6,191,139

Title: Medical use for tachykinin antagonists
Abstract:The present invention relates to the use of NK.sub.1 antagonists, in the treatment of depression. Also described are novel NK.sub.1 antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. The compounds of formula I are as follows: having a formula (I) ##STR1## wherein R represents the ring A ##STR2## or 2-pyridinyl or 2-pyridinyl-N-oxide; R.sup.1 is selected from the group consisting of halogen atoms, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, and S(O).sub.n C.sub.1-4 alkyl groups; R.sup.2 and R.sup.3, which may be the same or different, each independently are selected from the group consisting of hydrogen atoms, halogen atoms, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl and cyano groupss; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.
Inventor(s): Hagan; Russell Michael (Ware, GB)
Assignee: Glaxo Group Limited (Greenford, GB)
Filing Date:May 14, 1999
Application Number:09/311,570
Claims:1. A method for treating depression in a mammal which comprises administering to said mammal an anti-depressive amount of an NK.sub.1 antagonist and a pharmaceutically acceptable carrier.

2. A method for treating depression in a mammal which comprises administering to said mammal an anti-depressive amount of an NK.sub.1 antagonist and a pharmaceutically acceptable carrier, wherein the NK.sub.1 antagonist is a compound having a formula (I) ##STR31##

wherein

R represents the ring A ##STR32##

or 2-pyridinyl or 2-pyridinyl-N-oxide;

R.sup.1 is selected from the group consisting of halogen atoms, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, and S(O).sub.n C.sub.1-4 alkyl groups;

R.sup.2 and R.sup.3, which may be the same or different, each independently are selected from the group consisting of hydrogen atoms, halogen atoms, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl and cyano groupss;

n represents zero, 1 or 2;

and pharmaceutically acceptable salts and solvates thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc